

ACL Laboratories COVID-19 and Influenza Activity Report

Updated: November 28, 2020




Respiratory Pathogens - Nov 28, 2020

| Week | InfA-H1 | InfA-H3 | 2009 H1N1 | Inf B | RSV | All Para | EV / Rhino | Meta pneumo | Adeno | All Corona | Bocca | Myc. pneumo | Chlam. pneumo. | Leg. pneumo. | BP / BPP | Total Pos | POS FLU | Total | ACL RPPNL | US %FLU | IL/WI %FLU | ACL FLUPCR |
|--------|---------|---------|-----------|-------|-----|----------|------------|-------------|-------|------------|-------|-------------|----------------|--------------|----------|-----------|---------|-------|-----------|---------|------------|------------|
| Nov28 | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 0 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 13 | 0 | 161 | 0.0 | n/a | n/a | 0.0 |
| Nov21 | 0 | 0 | 0 | 0 | 0 | 0 | 13 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 0 | 140 | 0.0 | 0.2 | 0.1 | 0.0 |
| Nov 14 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 158 | 0.0 | 0.2 | 0.1 | 0.0 |
| Nov7 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 11 | 0 | 96 | 0.0 | 0.2 | 0.2 | 0.0 |
| Oct31 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 11 | 0 | 233 | 0.0 | 0.1 | 0.2 | 0.0 |
| Oct23 | 0 | 0 | 0 | 0 | 0 | 0 | 12 | 3 | 2 | 0 | 2 | 0 | 0 | 0 | 0 | 19 | 0 | 173 | 0.0 | 0.2 | 0.4 | 0.0 |
| Oct 16 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 1 | 1 | 0 | 2 | 0 | 0 | 0 | 0 | 17 | 0 | 185 | 0.0 | 0.3 | 0.2 | 0.0 |
| Oct9 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 2 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 14 | 0 | 64 | 0.0 | 0.3 | 0.3 | 0.0 |
| Oct2 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 7 | 0 | 65 | 0.0 | 0.3 | 0.2 | 0.0 |
| Sep 25 | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 2 | 0 | 0 | 0 | 0 | 2 | 0 | 11 | 0 | 111 | 0.0 | 0.3 | 0.0 | 0.0 |
| Sep 19 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 28 | 0.0 | 0.4 | 0.3 | 0.0 |
| Sep 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 58 | 0.0 | 0.2 | 0.0 | 0.0 |
| Sep 4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 146 | 0.0 | 0.2 | 0.5 | 0.0 |
| Aug 28 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 55 | 0.0 | 0.3 | 0.4 | 0.0 |

| SARS-COV-2 | | | | | RSV | | | | Influenza | | | |
|------------|----------------|----------------|---------------|---------------|----------------|----------------|---------------|---------------|----------------|----------------|---------------|---------------|
| Week | IL % SCVPCR | WI % SCVPCR | IL % COVAG | WI % COVAG | IL % RSVPCR | WI % RSVPCR | IL % RSVAG | WI % RSVAG | IL % FLUPCR | WI % FLUPCR | IL % FLUAG | WI % FLUAG |
| NOV 28 | 17.7 | 16.0 | 30.5 | 30.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| NOV 21 | 16.5 | 14.0 | 25.1 | 24.5 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | 2 |
| NOV 14 | 16.8 | 13.9 | 30.2 | 32.5 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | 0 |
| NOV 7 | 13.6 | 15.8 | 30.9 | 36.7 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| OCT 31 | 9.0 | 12.1 | 28.5 | 32.3 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| OCT 24 | 8.2 | 9.5 | 21.0 | 29.1 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| OCT 16 | 5.8 | 7.5 | 18.3 | 25.8 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| OCT 9 | 5.8 | 4.6 | 14.4 | 20.9 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| OCT 2 | 4.2 | 3.8 | n/a | 19.4 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| Sep 25 | 3.9 | 3.6 | n/a | 18.3 | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |
| Sep 19 | 4.3 | 3.4 | n/a | n/a | 0 | 0 | 0 | 0 | 0 | 0 | n/a | n/a |

ACL COVAG and SCVPCR - Pos rate Nov 28, 2020



COVAG Antigen rapid test – is performed at **Urgent Care** sites.

SCVPCR - Rapid PCR - test is performed using Cepheid PCR at AAH **Hospital** sites.

CDC- IL State Covid Cases Nov 28, 2020




7 day moving average of daily cases per 100k people

CDC- WI State Covid Cases Nov 28, 2020




7 day moving average of daily cases per 100k people



Nov 28th daily COVID-19 cases in US - CDC



US COVID-19 Case Rate Reported to the CDC in the Last 7 Days, by State/Territory (cases per 100K)




ACL FLUAG and FLUPCR - Pos rate Nov 28, 2020



FLUAG Antigen rapid test – is performed at **Urgent Care** sites.



FLUPCR - Rapid PCR - test is performed using Cepheid PCR at AAH **Hospital** sites.

Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2020-2021 Season




2020-21 Influenza Season Week 47 ending Nov 21, 2020


ILI Activity Level




RSV PCR for HHS Region 5 - Chicago (3 week average)




CSF targets positivity rate is 2.2 %



The most prevalent GI bacterial targets (Shiga Tox2)



The most prevalent GI viral targets - none



| Women's Health - Nov 28 2020 positivity rate (%) | | | | |
|--|--------------|---------------|------------|---------------|
| Bacterial Vag. | Candida spp. | Candida glab. | Trich. vag | M. genitalium |
| 29 | 21 | 2 | 3 | 8 |

Women Health SwabOne - Prevalence rate (%)

- M. genitalium
- Trich. vag.
- Candida glab.
- Candida spp.
- Bact. Vag.

